GGrantIndex
Sort

48,018 grants matching immunotherapy

Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity

$610,783
Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2025 · CA

Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity

$610,783
Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2024 · CA

Role of DeltaNp63 alpha and TIP60 in SCC progression and chemoresistance

$610,770
Madhavi P Kadakia · Wright State University · R01 · FY2025 · CA

Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition

$610,766
Jeffrey S Weber · New York University School Of Medicine · R01 · FY2020 · CA

Novel Approaches to CD33-Directed Radioimmunotherapy

$610,755
Roland Bruno Walter · Fred Hutchinson Cancer Center · R37 · FY2022 · CA

Regulation of anti-tumor immunity by HDAC11

$610,695
Edward Seto · George Washington University · R01 · FY2020 · CA

Study of CAR T cells and mechanisms of resistance in pediatric brain tumors

$610,644
Anandani Nellan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Host Response to TB and AIDS

$610,625
New York University School Of Medicine · R01 · FY2004 · HL

EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES

$610,603
Brad Kahl · University Of Wisconsin-Madison · U10 · FY2008 · CA

Mechanoimmunological interactions between TCR-T cells and tumor fibrotic microenvironment

$610,531
Ruogang Zhao · State University Of New York At Buffalo · R01 · FY2023 · CA

New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B

$610,511
Larisa Y Poluektova · University Of Nebraska Medical Center · R01 · FY2022 · AI

Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion

$610,423
Ioannis Vlachos · Beth Israel Deaconess Medical Center · R01 · FY2023 · CA

Development of small molecule selective inhibitors of neuronal nitric oxide synthase (nNOS) for melanoma treatment

$610,415
Sun Yang · Chapman University · R01 · FY2025 · CA

The use of chitosan for cancer vaccine delivery

$610,288
John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Targeting the Immune System in Mouse Models of Lung Adenocarcinoma

$610,279
Katerina Abigail Politi · Yale University · R01 · FY2015 · CA

T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade

$610,178
Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2024 · CA

Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance

$610,140
Linghua Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Programming multi-pronged immune response to glioblastoma with IL-13Ra2/TGF-b CAR-T cell therapy.

$610,097
Yvonne Yu-Hsuan Chen · University Of California Los Angeles · R01 · FY2025 · NS

Brain Tumors - Immunological and Biological Studies

$609,977
Duke University · R37 · FY2003 · CA

ASSESSMENT OF ENDOGENOUS AND CAR T-CELL IMMUNITY FOLLOWING ANTI-PD-1 AGENT AS A TRANSITION STEP TO PHASE 2 COMBINATION IMMUNOTHERAPY

$609,922
Sloan-Kettering Institute For Cancer Research · · FY2019 · Department of the Army

Immune Impact on Cancer Chemoresistance

$609,903
Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2017 · CA

Memory, Phenotype, and Function of TB-reactive Human MR1 Restricted T cells

$609,882
David M. Lewinsohn · Oregon Health & Science University · R01 · FY2020 · AI

High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy

$609,879
Udai S Kammula · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Immunotherapy Strategies for Uveal Melanoma

$609,879
Udai S Kammula · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Regulating the glioma immune microenvironment

$609,700
Joanna Phillips · University Of California, San Francisco · R01 · FY2025 · NS